Kafukufuku wa Gawo I adachitika kwa odwala azaka za 45-80 omwe adadwala matenda a ischemic stroke. Magazi a umbilical cord adatengedwa kuchokera ku StemCyte's public cord blood inventory based on ABO/Rh blood type, Human Leukocyte Antigen (HLA) machesi > 4/6, ndi cell dose of total mononuclear cell (MNC) count ya 0.5-5 x 107 ma cell / kg. Kuonjezera apo, Mlingo wa mannitol anayi (4) 100 ml wa mannitol unkaperekedwa kudzera m'mitsempha kwa mphindi 30 pambuyo poika magazi m'mitsempha ndi maola 4 aliwonse pambuyo pake.
Zotsatira zoyambirira zinali chiwerengero cha odwala omwe adayambitsa matenda a graft versus host (GVHD) mkati mwa masiku 100 atayikidwa. Zotsatira zachiwiri zinali kusintha kwa National Institutes of Health Stroke Scale (NIHSS), Barthel index, ndi Berg Balance Scale scores. Nthawi ina, wodwala wazaka 46 wazaka zakubadwa yemwe ali ndi mbiri ya matenda oopsa komanso hemodialysis chifukwa cha matenda omaliza aimpso adathandizidwa mosiyanasiyana pogwiritsa ntchito hUCB yokhala ndi ABO / Rh yofananira, machesi a 6/6 a HLA, ndi kuchuluka kwa MNC kwa 2.63 x 108 maselo/kg. Wodwalayo sanaperekedwe ndi zochitika zovuta kwambiri kapena GVHD pa phunziro la mwezi wa 12. Zotsatira zake za NIHSS zidatsika kuchokera ku 9 mpaka 1; chiwerengero cha Berg Balance Scale chinawonjezeka kuchokera ku 0 mpaka 48, ndipo chiwerengero cha Barthel chinawonjezeka kuchokera ku 0 mpaka 90. Kafukufuku woyambirirayu anasonyeza kuti wodwala wamkulu yemwe ali ndi hemiplegia chifukwa cha ischemic stroke adachira kwathunthu mkati mwa miyezi 12 atalandira chithandizo cha UCB cha allgeneic.
"Ndife okondwa kwambiri ndi zotsatira zabwino zachipatala za maphunziro a StemCyte's Phase I," atero Purezidenti wa StemCyte ndi Wapampando Jonas Wang, PhD. "Pokhala ndi sitiroko yowopsa yomwe ili yachiwiri ndi yachitatu yomwe imayambitsa imfa ndi kulumala, motsatana, padziko lonse lapansi, izi ndi zachilendo monga momwe zinalili zosayembekezereka." Pafupifupi 30% -35% ya anthu omwe akudwala sitiroko amafa ndipo pafupifupi 75% ya opulumuka amakhala olumala kosatha. Thandizo lamakono mu gawo lopweteka limaphatikizapo kugwiritsa ntchito thrombolytic, anticoagulant, ndi antiplatelet agents. Komabe, kugwiritsa ntchito mankhwalawa kumawonjezera kuchuluka kwa magazi ndi 15% -20%.
Maselo amtundu wa zingwe amachulukana kukhala ma cell a neural, ndipo adapezeka kuti ndi othandiza pochiza matenda angapo a neurodegenerative. Mu cerebral stroke, jakisoni wa UCB ndi MNCs amatha kubwezeretsanso luso lochita masewera olimbitsa thupi komanso kupereka zotsatira za neuroprotective zomwe zikuwonetsedwa ndi kuchepa kwa zizindikiro zotupa monga TNF-alpha, IL-1β ndi IL-2.
ZOMWE MUNGACHITE PA NKHANIYI:
- In one case, a 46-year-old male patient with a history of hypertension and hemodialysis for end-stage renal disease was treated allogeneically using hUCB with identical ABO/Rh, a 6/6 HLA match, and MNC count of 2.
- In cerebral stroke, the intravenous injection of UCB and MNCs could restore exercise abilities as well as provide neuroprotective effects as indicated by decreased expression of inflammatory markers such as TNF-alpha, IL-1β and IL-2.
- “With acute stroke being the second and third leading cause of death and disability, respectively, worldwide, this outcome is as outstanding as it was unexpected.
